Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592356 · ClinicalTrials.gov registry record · NA
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02592356: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT02592356 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02592356, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
Interventions
- PROCEDURE Computed Tomography
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- PROCEDURE Physical Examination
- PROCEDURE Dual X-ray Absorptiometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2024-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02592356
The ClinicalTrials.gov registry entry for NCT02592356 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography is the first listed.
NCT02592356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02592356 about?
NCT02592356 is a clinical study titled "Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer". The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.
What is the current status of trial NCT02592356?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2015-11-16. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT02592356?
The interventions under investigation include: Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Physical Examination (PROCEDURE), Dual X-ray Absorptiometry (PROCEDURE).
Who is sponsoring clinical trial NCT02592356?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.